AbbVie Inc. Accounts Receivable, Allowance for Credit Loss, Current
AbbVie Inc. (ABBV) had Accounts Receivable, Allowance for Credit Loss, Current of $262.00 million as of 2020-12-31, per its 10-K filed 2021-02-19.
Discontinued › Balance Sheet › Assets › Receivables, Net, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2021-02-19
- 2020-12-31: Accounts Receivable, Allowance for Credit Loss, Current $262.00M.
- 2019-12-31: Accounts Receivable, Allowance for Credit Loss, Current $46.00M.
- 2018-12-31: Accounts Receivable, Allowance for Credit Loss, Current $51.00M.
- 2017-12-31: Accounts Receivable, Allowance for Credit Loss, Current $58.00M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2020-12-31 | $262.00M 10-K · filed 2021-02-19 |
| 2019-12-31 | $46.00M 10-K · filed 2020-02-21 |
| 2018-12-31 | $51.00M 10-K · filed 2020-02-21 |
| 2017-12-31 | $58.00M 10-K · filed 2019-02-27 |
| 2016-12-31 | $72.00M 10-K · filed 2018-02-16 |
| 2015-12-31 | $78.00M 10-K · filed 2017-02-17 |
| 2014-12-31 | $74.00M 10-K · filed 2016-02-19 |
| 2013-12-31 | $88.00M 10-K · filed 2015-02-20 |
| 2012-12-31 | $83.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |